Clinical Trial: HY001N for Patients With Autoimmune Hemolytic Anemia After Failure >=3 Lines of Therapy.

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07748533) titled 'HY001N for Patients With Autoimmune Hemolytic Anemia After Failure >=3 Lines of Therapy.' on June 25.

Brief Summary: The goal of this clinical trial is to learn if HY001N cell injection safety and tolerability in adult patients with autoimmune hemolytic anemia after failure of 3 or more lines of therapy. It will also learn about the efficacy of HY001N cell injection to treat adult patients with autoimmune hemolytic anemia. The main questions it aims to answer are:

Proportion of participants attaining a CR (defined as normalization of hemoglobin not attributed to transfusion effect and the normalization of hemolytic markers) or CRi (...